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Introduction {#sec001}
============

Since the early 2000s, cases of severe malaria associated with *Plasmodium vivax* have been described in Brazil and other endemic regions \[[@pone.0224877.ref001]--[@pone.0224877.ref004]\]. In 2015, severe vivax malaria was responsible for causing around 16% of all malaria mortality outside the sub-Saharan region \[[@pone.0224877.ref005]\]. In Indonesia and in non-endemic areas of India, *P*. *vivax* infection rates have been reported to be comparable to the rates of *P*. *falciparum* infection \[[@pone.0224877.ref006], [@pone.0224877.ref007]\]. In Latin America, severe vivax malaria began to acquire importance in 2009, when the number of serious cases of the disease increased significantly \[[@pone.0224877.ref008]--[@pone.0224877.ref010]\].

The main complications associated with severe vivax malaria are thrombocytopenia, hemoglobinuria, and respiratory failure. In a systematic review, Rahimi et al. (2014) showed that patients with severe *P*. *vivax* may complicate with liver dysfunction, circulatory shock, respiratory difficulty, renal failure, severe anemia, and central nervous system involvement \[[@pone.0224877.ref011]\]. A cohort study performed in southwest India demonstrated changes in respiratory frequency and in serum levels of total bilirubin, creatinine serum, and hemoglobin dosage associated with *P*. *vivax* infection. These findings are now considered independent predictors for severe vivax malaria \[[@pone.0224877.ref012]\]. Additionally, a significant reduction in the number of platelets, leukocytes, lymphocytes, eosinophils, red blood cells, and hemoglobin has been observed in the hematologic profile of patients with acute *P*. *vivax* infection \[[@pone.0224877.ref013], [@pone.0224877.ref014]\].

Several serum markers have been used as tools to assess the potential severity of various diseases, including dengue, cirrhosis and viral hepatitis, and malaria \[[@pone.0224877.ref015]--[@pone.0224877.ref020]\]. In severe liver diseases, biochemical assays have been tested for their diagnostic and prognostic potential. One minimally invasive biochemical assay is the aspartate aminotransferase-to-platelet ratio index (APRI), determined by the patient\'s aspartate aminotransferase (AST) level (corrected for that enzyme's upper limit of normality in the blood) divided by the patient's platelet count \[[@pone.0224877.ref021]\]. A meta-analysis of patients with hepatocellular carcinoma confirmed that the APRI is associated to liver function deterioration and could be used as a stable and reliable marker to predict tumor progression. In addition, APRI values are associated with the prognosis of several other neoplasms and human infections, including chronic hepatitis C \[[@pone.0224877.ref022]\].

For non-hepatic infectious diseases, there is not much information using the APRI as a marker of disease severity. It is known that the liver is an important target in *P*. *falciparum* and *P*. *vivax* infections: hepatic damage was clinically demonstrated due to an intense inflammatory response and oxidative stress. Plasmodium-induced histopathological changes in the liver include hepatocyte necrosis, granulomatous lesions, hyperplasia of Kupffer cells, phagocytosis of malarial pigment, cholestasis, and infiltration of monocytes. Such changes can alter the levels of transaminases, even in cases of non-severe disease, which may return to normal after treatment \[[@pone.0224877.ref023]\].

Early diagnosis of malaria parasite-induced complications and their precise treatment are important for preventing disease progression and death. Thus, easily obtained biochemical markers, such as the APRI, may function as important tools for identifying the presence of hepatic damage and, consequently, identifying patients with a higher potential for disease progression during the acute phase of *P*. *vivax* malaria. The main objective of this study was to evaluate the APRI as a diagnostic tool for identifying patients at risk of *P*. *vivax* malaria severity. For this purpose, a clinical assessment (based on the severity criteria for *P*. *falciparum* malaria) evaluated patients for signs, symptoms, and laboratory changes indicative of severe vivax malaria.

Patients and methods {#sec002}
====================

Study design and population {#sec003}
---------------------------

In this cross-sectional study, a retrospective analysis was performed on the routine laboratory test results of 130 patients with acute *P*. *vivax* infection that received care in the period from 2011 to 2018 at the Júlio Müller University Hospital in Cuiabá, Mato Grosso, Central Region of Brazil. All the study participants were outpatients and only attended the hospital for the first medical evaluation, not returning for clinical follow-up. Therefore, no follow-up information on disease progression was obtained in the study. At this hospital all suspected malaria patients undergo careful clinical and laboratory examination by doctors. Thick smear for *Plasmodium* screening, blood cell count, and basic blood biochemistry were performed at the first patient consultation. After careful review of the medical records, patients with other concomitant infections, such as hepatitis B, hepatitis C, dengue, HIV, or bacterial infection, were excluded from this analysis. Patients with arterial hypertension, ischemic cardiopathy, a history of myocardial infarction or cerebrovascular accident, diabetes mellitus, chronic liver disease, history of malignant disease, or neurological or psychiatric diseases were also excluded. Treatment for all patients was provided in compliance with the recommendations of the Ministry of Health for the treatment of *P*. *vivax* infections \[[@pone.0224877.ref024]\].

*P*. *vivax* infection was diagnosed by microscopic examination of the blood and subsequently confirmed by PCR in accordance with the protocol described by Snounou et al. (1993) \[[@pone.0224877.ref025]\]. Microscopy was used to quantify parasite density by enumerating all the parasite's asexual blood stages in 500 leukocytes.

Classification of groups according to severity {#sec004}
----------------------------------------------

The WHO-established criteria for defining severe *P*. *falciparum* malaria were adapted in order to stratify patients into groups based on disease severity in the acute phase of *P*. *vivax* malaria \[[@pone.0224877.ref005]\]. As the AST, a biomarker of liver disease severity, was used in this study, jaundice, hyperbilirubinemia, and elevated hepatic enzymes \[[@pone.0224877.ref026]\] were not included as criteria for severe malaria in the present analysis. Similarly, the platelet count has not been considered an associated parameter with severe malaria \[[@pone.0224877.ref027]\].

Adaptations were made to the criteria of acute renal insufficiency and hyperparasitemia, as these are the most questioned in the medical literature \[[@pone.0224877.ref030], [@pone.0224877.ref031]\]. The threshold level of serum creatinine was adapted to be above 1.5 mg/dL (already used in other studies \[[@pone.0224877.ref032], [@pone.0224877.ref031]\]) and the threshold for parasitic density was adapted to be over 20,000/μL, although there are references to even smaller cutoff points for parasitemia associated with severe *P*. *vivax* in the medical literature \[[@pone.0224877.ref033], [@pone.0224877.ref034]\].

Determination of APRI values {#sec005}
----------------------------

The clinical and biochemical alterations used for evaluation of hepatic damage in study patients were jaundice as well as elevated levels of total bilirubin serum, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase \[[@pone.0224877.ref023]\]. Patient serum was analyzed by the photometric method in a BT-3000 Plus automated biochemical analyzer (Diamond Diagnostics, Cambridge, MA, USA). Patient platelet count was enumerated using a hematologic multiparameter analyzer (Pentra 80, Horiba Medical, Montpellier, France). The APRI was calculated using the following formula: $$APRI = \frac{\frac{AST\ \left( UI/L \right)}{Upper\ limit\ of\ AST}}{{Plaques\ x\ 10}^{9}/L}\ x\ 100$$

Data analysis {#sec006}
-------------

All statistical analyses were performed using the *Stata* package version 12.0. Patient age was described and analyzed as a continuous variable. Patient age was stratified into four age groups in accordance with WHO guidelines \[[@pone.0224877.ref035]\]. In this study, platelet count, to identify thrombocytopenia, was stratified into severe (\< 50,000 platelets/μL) and moderate (between 50,000 and 150,000 platelets/μL), as previously described \[[@pone.0224877.ref015], [@pone.0224877.ref036]\]. Chi‐squared or Fisher\'s exact test was used to compare categorical variables. Chi-squared test for linear trend was used to analyse trend in proportions. The Shapiro-Wilk test was used to verify whether the biochemical and hematological results had a normal distribution. Since all the parameters analyzed showed abnormal distributions, the non-parametric Mann-Whitney test was applied to compare the continuous variables between groups. Values of p \< 0.05 were considered significant for all the analyses.

To assess the discriminatory power of the APRI as a readout for groups with and without signs of severe *P*. *vivax* infection, a ROC (receiver operating characteristic) curve was graphed. The area under the ROC curve was analyzed and its respective 95% confidence interval was calculated assuming a non-parametric distribution. The concordance probability as described by Liu was utilized to define the cutoff point for the APRI that yielded the greatest sensitivity and specificity values along with the lowest probability of chance occurrence \[[@pone.0224877.ref037]\]. This method of obtaining a cutoff point is recommended when the analysis objective is to determine values that maximize sensitivity or specificity for clinical decision making \[[@pone.0224877.ref038]\].

Ethics statement {#sec007}
----------------

The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the Júlio Müller University Hospital (CEP number 130/HUJM/2011). Written informed consent was obtained from all patients after suitable explanation about the research. For participants under 18 years of age, consent was obtained from parents or guardians.

Results {#sec008}
=======

We analyzed 189 medical records from eligible patients with symptomatic malaria caused by microscopy and PCR-confirmed monoinfection with *P*. *vivax*. Fifty-nine patients were not included in the study because lack of clinical or laboratorial data, and presence of comorbidities. The remained 130 patient's records were included in this analysis. Of these patients, 100 (76.9%) were male and 30 (23.1%) were female. Their ages ranged from 1 to 78 years with a mean of 38.4 years and standard deviation (SD) of 15.4 years. A majority (70%) of patients reported less than 7 days of symptoms ([Table 1](#pone.0224877.t001){ref-type="table"}). All patients declared to have had fever in the 24 hours prior to entering the study.

10.1371/journal.pone.0224877.t001

###### Characteristics of the *Plasmodium vivax* infected patients, according to presence and absence of signs of severe vivax malaria.

![](pone.0224877.t001){#pone.0224877.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                Sign of\               Total (%)              p                                                                         
                                severity                                                                                                                
  ----------------------------- ---------------------- ---------------------- ---------------------- -------------------------------------------------- ----------------------------------------------
  Gender                        *Male*                 17 (17,0)              83 (83,0)              100 (76,9)                                         0,262[\*](#t001fn002){ref-type="table-fn"}

  *Female*                      2 (6,7)                28 (93,3)              30 (23,1)                                                                 

  Age (years)                   *1--4*                 0 (0,0)                1 (100,0)              1 (0,8)                                            0,465[\*\*](#t001fn003){ref-type="table-fn"}

  *5--19*                       1 (7,7)                12 (92,3)              13 (10,0)                                                                 

  *20--49*                      10 (11,9)              74 (88,1)              84 (64,6)                                                                 

  *≥ 50*                        8 (25,0)               24 (75,0)              32 (24,6)                                                                 

  ***Mean (SD)***               **43,0 (17,6)**        **37,6 (15,0)**        **38,4 (15,4)**        0,173[^\#^](#t001fn004){ref-type="table-fn"}       

  Symptoms onset time (days)    *1--2*                 5 (26,3)               17 (73,7)              22 (16,9)                                          0,431[\*\*](#t001fn003){ref-type="table-fn"}

  *3--7*                        8 (11,6)               61 (88,4)              69 (53,1)                                                                 

  *≥8*                          6 (15,4)               33 (84,6)              39 (30,0)                                                                 

  Jaundice                      *Present*              4 (33,3)               8 (66,7)               12 (9,2)                                           0,054

  *Absence*                     15 (12,7)              103 (87,3)             118 (90,8)                                                                

  Total bilirubin               *Normal*               15 (13,8)              94 (86,2)              109 (83,8)                                         0,530

                                *Altered*              4 (19,0)               17 (81,0)              21 (16,2)                                          

  ALT (IU/L)\                   *Normal*               18 (16,2)              93 (83,8)              111 (85,4)                                         0,377[\*](#t001fn002){ref-type="table-fn"}

  *Altered*                     1 (5,3)                18 (94,7)              19 (14,6)                                                                 

  AST (IU/L)\                   *Normal*               18 (14,4)              107 (85,6)             125 (96,2)                                         0,999

  *Altered*                     1 (20,0)               4 (80,0)               5 (3,8)                                                                   

  Alkaline phosphatase (IU/L)   *Normal*               14 (13,6)              89 (86,4)              103 (79,2)                                         0,519

  *Altered*                     5 (18,5)               22 (81,5)              27 (20,8)                                                                 

  Platelets\                    *15*.*000--50*.*000*   5 (22,7)               17 (77,3)              22 (17,1)                                          0,032[\*\*](#t001fn003){ref-type="table-fn"}
  (cells/ μL)                                                                                                                                           

  *50*.*000--150*.*000*         13 (16,5)              66 (83,5)              79 (61,2)                                                                 

  *\>150*.*000*                 1 (3,6)                27 (96,4)              28 (21,7)                                                                 

  ***Mean (SD)***               **80.263 (47.621)**    **110.913 (57.264)**   **106.433 (56.840)**   **0,019**[^\#^](#t001fn004){ref-type="table-fn"}   

  APRI                          *0--1*,*50*            10 (10,0)              90 (90,0)              100 (76,9)                                         0,007

  *\> 1*,*50*                   9 (30,0)               21 (70,0)              30 (23,1)                                                                 

  ***Mean (SD)***               **2,11 (2,64)**        **1,09 (1,14)**        **1,24 (1,49)**        **0,044**[^\#^](#t001fn004){ref-type="table-fn"}   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AST: aspartate aminotransferase; ALT: alanine aminotransferase; IU/L: International Units per Liter; APRI: Aspartate aminotransferase-to-platelet ratio index; SD: Standard Deviation. p value determined by chi-squared test

\* Fisher's exact test

\*\* Chi-squared test for linear trend

^\#^ Man-Whitney test

Of the 130 patients, 19 (14.6%) had one or more of the signs and symptoms used in this study to indicate severe vivax malaria. The following clinical and laboratory abnormalities suggestive of hepatocyte damage were observed: jaundice (9.2%), total hyperbilirubinemia (16.2%), high alkaline phosphatase (20.1%), high ALT (14.6%), and high AST (3.9%). However, none of these clinical and laboratory abnormalities were significantly associated with indicators of severity of acute vivax malaria. However, most patients (78.5%) had low platelet counts (less than 150,000/ platelets/μL). The mean number of platelets in the severe group was 80,263 cells/μL (SD 46,621), which was significantly lower than that of patients without signs of severe disease (p = 0.019). Severe thrombocytopenia, between 15,000 and 100,000 platelets/μL, was found in 17.1% of the patients. A negative association (p = 0.032) between degree of thrombocytopenia and presence of signs of severe disease was observed as compared to patients with normal platelet counts ([Table 1](#pone.0224877.t001){ref-type="table"}).

The average APRI value was 1.24 (SD 1.49). The average APRI was significantly higher \[2.11 (SD 2.64) vs. 1.09 (SD 1.14); p = 0.044\] in the group with signs of severe vivax malaria. APRI values above 1.50 showed a significant association (p = 0.007) with signs of severe disease during acute *P*. *vivax* infection ([Table 1](#pone.0224877.t001){ref-type="table"} and [Fig 1](#pone.0224877.g001){ref-type="fig"}).

![Aspartate aminotransferase-to-platelet ratio index (APRI) in patients infected with *P*. *vivax* with presence or absence of signs and symptoms of severe malaria.](pone.0224877.g001){#pone.0224877.g001}

For all APRI values, the area under the ROC curve (95% CI) was 0.645 (0.494; 0.795). A cutoff of 0.74 resulted in sensitivity of 74.0%, specificity of 56.0%, and accuracy of 65.0% for diagnosing patients at risk of severe disease due to *P*. *vivax* infection ([Fig 2](#pone.0224877.g002){ref-type="fig"}).

![ROC curve for the use of the aspartate aminotransferase-to-platelet ratio index (APRI) as a biomarker to diagnose patients at risk of severe malaria due to *P*. *vivax* infection.\
A cutoff of 0.74 yielded a sensitivity of 74.0%, specificity of 56.0%, and accuracy of 65.0%.](pone.0224877.g002){#pone.0224877.g002}

Discussion {#sec009}
==========

In the present study, low platelet count and high APRI were significantly associated with the presence of clinical and laboratory manifestations of severe malaria in patients during the acute phase of *P*. *vivax* infection. An APRI cutoff of 0.74 was reasonably sensitive for identification of patients with a higher potential for severe disease. Despite the low specificity and the small number of patients in this sample, the discovery of the APRI as a sensitive biomarker of severe vivax malaria is very promising.

According to the WHO, studies conducted in reference hospitals in which it is possible to identify the *Plasmodium* species causing malaria provide more reliable estimates of severe malaria occurrence and mortality risk \[[@pone.0224877.ref039]\]. The development of simple and sensitive tools to predict severe disease is greatly needed. The APRI is one possible tool to suit this purpose because it is low cost and easy to obtain.

Little is known about the mechanisms involved in the recent emergence of severe *P*. *vivax* infections. Drug resistance, parasite genotype selection, and changes in the host inflammatory response may have contributed to this clinical phenomenon \[[@pone.0224877.ref040]\]. For this reason, the same clinical and laboratory parameters for severe *P*. *falciparum* infection have been used to define severe *P*. *vivax* malaria \[[@pone.0224877.ref041]\]. There is little information on inflammatory biomarkers related to severe disease. Some studies have evaluated thrombocytopenia \[[@pone.0224877.ref027]\], changes in platelet parameters \[[@pone.0224877.ref042]\], serum levels of angiopoietin I and II \[[@pone.0224877.ref015]\], and the presence of some non-coding RNA molecules \[[@pone.0224877.ref043]\] with some success but low precision. Thrombocytopenia, although frequently reported during the acute phase of vivax malaria, is not considered a predictor of severe malaria with *P*. *vivax* or *P*. *falciparum* infection \[[@pone.0224877.ref027], [@pone.0224877.ref028]\]. Similarly, other hematological and biochemical changes caused by infection with *P*. *vivax* have already been studied as diagnostic and/or prognostic markers of severe disease \[[@pone.0224877.ref027]\]. However, there is no information in the medical literature about the use of the APRI in malaria.

Altered hematological parameters were infrequent in the present study and were not associated with the presence of severe symptoms, except for platelet count, which was significantly lower among patients with signs of severe disease. Low platelet count associated with *P*. *vivax* has already been demonstrated in other studies conducted in Brazil and India \[[@pone.0224877.ref044], [@pone.0224877.ref045], [@pone.0224877.ref028], [@pone.0224877.ref015]\]. Because it occurs more frequently in *P*. *vivax* than *P*. *falciparum* infections, thrombocytopenia has already been evaluated as a parameter to distinguish between species of *Plasmodium* in human infections. However, this method was tested without success \[[@pone.0224877.ref044]\]. More recently, a study conducted in South America showed that thrombocytopenia was one of the most altered hematological parameters in severe infections, regardless of species, with 90% of patients having platelet counts lower than 150,000/ μL and 43% of the population surveyed were \< 50,000/ μL \[[@pone.0224877.ref046]\].

In the present study, serum levels of total bilirubin and liver enzymes were not different between the groups. However, it is known that *P*. *vivax* induces damage to the liver and can cause changes in bilirubin and hepatocytic enzyme levels, which may result in liver dysfunction \[[@pone.0224877.ref039]\]. A previous study showed that serum levels of bilirubin, aspartate aminotransferase, and alkaline phosphatase were significantly higher in patients considered to have severe *P*. *vivax* infections \[[@pone.0224877.ref012]\].

In recent years, the combined analysis of liver enzymes and platelet counts has provided important information regarding the role of new biomarkers in predicting neoplastic and infectious disease severity \[[@pone.0224877.ref047], [@pone.0224877.ref048]\]. One of these biomarkers, the APRI, has been widely studied as a minimally invasive marker of fibrosis and inflammation in hepatic disease \[[@pone.0224877.ref049], [@pone.0224877.ref050]\]. The APRI has also proven useful in predicting the severity of acute and systemic diseases such as dengue \[[@pone.0224877.ref019]\] and HELLP syndrome \[[@pone.0224877.ref051]\]. For this reason, we hypothesized that the APRI is altered in the acute phase of malaria since the liver is also targeted by *Plasmodium* \[[@pone.0224877.ref023]\].

In this study, APRI values were significantly higher among patients with danger signs of severe disease during acute *P*. *vivax* infection compared to those without signs of severity. This suggests a necro-inflammatory process as a pathophysiological mechanism for the increase in the APRI. The usefulness of the APRI was well-demonstrated in a 9-year longitudinal study of patients with HIV/viral hepatitis co-infection and paired controls. APRI values were stable among controls but increased 30% during the 3 years preceding death. The authors concluded that the rapid increase in APRI may predict imminent liver-related death in HIV/viral hepatitis co-infection \[[@pone.0224877.ref052]\]. This biomarker of hepatic fibrosis has been widely used in patients with hepatocellular carcinoma, cirrhosis, and chronic hepatitis B and C \[[@pone.0224877.ref020], [@pone.0224877.ref021], [@pone.0224877.ref053]--[@pone.0224877.ref055]\].

There is strong evidence of the clinical value of the APRI in predicting liver inflammation of various etiologies \[[@pone.0224877.ref056]\]. In a recent and pioneering study on the importance of the APRI as a predictor of signs of dengue severity, the authors concluded that the APRI proved to be an independent and more valuable predictor to discriminate patients with severe forms of the disease than individual changes in hematological and biochemical parameters \[[@pone.0224877.ref019]\].

In the present study, APRI accuracy for diagnosing patients at risk of severe vivax malaria was 64.5%, with sensitivity of 74.0%, and specificity of 56.0%. Despite the low specificity, these values are close to those observed in another study that used the APRI to predict chronic liver diseases in pregnant women. In the aforementioned study, the sensitivity, specificity, and accuracy were 83%, 55%, and 64%, respectively \[[@pone.0224877.ref049]\]. It is interesting to note that for this study, the greater sensitivity relative to specificity for the APRI does not invalidate its possible clinical application since it is preferable to identify patients with a higher risk of developing severe disease early, even at the risk of erroneous classification due to the high probability of false positives. In addition, it should be noted that the accuracy of other biomarkers proposed for the same purpose, such as the angiopoietin I/angiopoietin II ratio for the prediction of severe vivax malaria, are similar to the value reported here \[[@pone.0224877.ref015]\].

Some limitations should be considered in the final interpretation of the present study's results. First, there was a low number of patients with signs of severe *P*. *vivax* infection. Second, we adapted the criteria established by the WHO for the definition of severe falciparum malaria, mainly a parasitemia threshold of 20,000/μL, for vivax malaria.

Among the problems related to the definition of severe vivax malaria is the lack of standardized criteria for severity in both clinical and research settings. The WHO criteria have been criticized for being overly sensitive; they are clinically useful since they detect extremely severe patients, but are less useful for research because they do not identify less severe patients \[[@pone.0224877.ref029], [@pone.0224877.ref030]\]. The preference of *P*. *vivax* for parasitizing young red blood cells (reticulocytes) could explain the higher frequency of low parasite counts observed for this species, even in severe malaria \[[@pone.0224877.ref029], [@pone.0224877.ref034]\]. One hospital-based study conducted in Indonesia showed much lower rates of parasitism (\> 6,000 parasites/μL) among hospitalized patients with severe and even fatal *P*. *vivax* infection \[[@pone.0224877.ref033]\]. The choice of a cutoff point for parasitemia of 20,000 parasites/μL was based on a study done in the Colombian Amazon, which showed parasitemia of less than 20,000 parasites/μL in 97% of patients with malaria not complicated by *P*. *vivax* \[[@pone.0224877.ref032]\].

In summary, this study indicates that routine laboratory tests, such as platelet count, liver enzyme dosage, and APRI determination, may help identify patients with greater potential for severe vivax malaria. A cutoff point of 0.74 for the APRI value has good sensitivity to identify patients with greater potential for severe disease during acute *P*. *vivax* infection. These findings point to the APRI as a promising biomarker of severity in acute *P*. *vivax* infections. However, longitudinal studies on more patients with severe disease are needed to confirm these findings and to support the clinical applicability of the APRI as a diagnostic and prognostic tool for severe acute *P*. *vivax* infection.

Conclusion {#sec010}
==========

Our results show that the APRI is elevated in patients with evidence of *P*. *vivax* infection. Based on the good APRI sensitivity found in this study, we conclude that this simple index can serve as a diagnostic biomarker to identify patients at risk of severe disease during the acute phase of *P*. *vivax* infection.

Supporting information {#sec011}
======================

###### Demographic, clinical and laboratory features of the studied patients.

(DOCX)

###### 

Click here for additional data file.
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3\. What do the authors refer to as noninvasive? Techniques involving biological samples from venous puncture are not invasive? I do no agree. Change across the manuscript.

4\. Methods:

\"Patients with other concomitant infections, such as hepatitis B, hepatitis C, dengue, HIV, or bacterial infection, were excluded from this analysis.\" Were they systematically tested? Clarify.

5\. \"Treatment for all patients was provided in compliance with the recommendations of the Ministry of Health for the treatment of P. vivax infections \[24\].\" Were all blood samples collected before treatment began? Clarify.

6\. What is \"microscopy optics\"?

7\. Discussion:

\"Drug resistance, genomic alterations in the parasite, and changes in the host inflammatory response may have contributed to this clinical phenomenon \[40\].\"

Genomic alterations? Change to parasite genotype selection or similar.

Reviewer \#2: Aspartate aminotransferase-to-platelet ratio index (APRI): a potential marker for diagnosis in patients at risk of severe malaria caused by Plasmodium vivax

Thank you for giving me an opportunity to review this paper. I have read this manuscript with keen interest. The authors have attempted a study with two objectives; i) to describe the clinical and laboratory characteristics of patients with P. vivax infection, and ii) to evaluate the APRI as a method of identifying patients with potentially severe disease.

This is an interesting research area in the light of malaria pre-/elimination context. However, I feel that the manuscript needs substantial improvement on an array of areas.

The followings are not exhaustive, only some examples to improve the quality of presentation.

Abstract

Please, update the abstract based on the comments given below.

Line\# 29...It should be better to describe as 'the objectives', rather than the goal.

Line \#32.... I feel, this is a retrospective cohort analysis of the clinical-epidemiological data. The study data were obtained from the medical records.

Line \# 38.. Please, clarify whether these are 130 patients or 130 patient's records.

Line \# 40..... It should read as 'severe vivax malaria'.

Line \# 44,45,47..... I feel, there is some exaggerations in interpretations.

The ROC value was 0.645 (0.494; 0.795), specificity was 56.0% and accuracy was 65.0%.

Line \# 47.......The authors have concluded that "This simple index can serve as a diagnostic biomarker........."..........The authors need to revise the interpretation and conclusion.

TEXT

A substantial improvement in English language/grammar/ punctuation are required throughout the manuscript.

Overall, the current version of manuscript is not well written.

Background

This section is not well written. Also, it is not in sequential order. There is redundant information.

The study objectives were not well described. I feel, there are two objectives. Please, explicitly describe the objectives.

Methods

Overall, this section is not well presented.

I feel, this is a retrospective cohort analysis of the patient's records. (Plese, see my comments to the abstract).

The authors need to improve this section. It will be better to follow the STROBE checklist.

Line\# 159.. The authors assessed whether there is normal distribution of the continuous data. This is an appreciable effort.

Line \# 160-61 The authors stated that they used a non-parametric Mann-Whitney test.

In Table 1 (Foot note)....... The results came out from the Fisher's exact test/Chi-squared test for linear trend. Please, clarify.

Results

Overall, this section is not well presented.

Table 1... Title is too long.

Table 1.. Only two parameters (Platelets and APRI ) are significantly different between the two groups.

Severe TCP ( n=1), APRI \> 1,5 (n = 9)

I feel, the authors can provide a correlation between these two parameters.

Line \# 200......... The average APRI value was 1.24. In Table 1, it was 1.2.

Two decimal or 1 decimal?

The authors stated, "An APRI cut-off of 0.74 was reasonably sensitive and specific for identification of patients with a higher potential for severe disease".

Please, consider that a chance of getting false positive is considerable (specificity 56%, accuracy 65%).

Line \# 268-269. For this reason, it is hypothesized that the APRI is .....;; by Plasmodium \[23\]. This supporting information is valuable, and it will be much better to describe under "Background".

Line \# 318.. A cut-off point of 0.74 for the APRI value has good sensitivity and specificity to identify ............. I feel, an exaggeration in interpretation as 74% is not representing the specificity. please, rephrase this sentence. \[Also, see my comments to the Abstract\].

Thank you

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewers

\- The authors thank the reviewers for their comments and suggestions, which they consider of great importance to improve the quality of the manuscript.

\- Al lines indicated in yellow collor for each response to the Reviewer's comment were identified in the 'Revised Manuscript With Track Changes file.

Reviewer´s Comments to the Author

Reviewer \#1:

The goal of the present study was to describe the clinical and laboratory characteristics of patients with acute P. vivax infection and evaluate the aspartate aminotransferase-to-platelet ratio index (APRI) as a method of identifying patients with severe disease. Some points to be clarified:

1\. What is \"potentially severe disease\", used several times across the manuscript. Please change to \"severe disease\" or \"severe malaria\".

\- Since the study design did not include patient follow-up to ensure progression to severity, the authors preferred to be careful in interpreting vivax malaria severity in this cross-sectional approach only. Therefore, throughout the manuscript, the inference about severity was parsimonious. We have replaced the term \"potentially serious\" to \"at risk of severity\". \[lines 32, 37, 48, 101, 104, 165, 191, 193, 195, 200, 209, 211, 2013, 217, 223, 232, 247, 249, 273-275, 289-290, 302, 304, 306, 331\].

2\. In Introduction: \"In contrast, monocyte and neutrophil counts are significantly higher in infected individuals compared to those not infected with Plasmodium \[13, 14\].\" If I understood correctly, this sentence is related to malaria infection rather than severe malaria. Delete it.

The sentence was removed as requested. \[lines 69-71\]

3\. What do the authors refer to as noninvasive? Techniques involving biological samples from venous puncture are not invasive? I do no agree. Change across the manuscript.

\- We agree with the reviewer. Blood collection is an invasive procedure, albeit a minor one. Thus we replaced the term "non-invasive" to "minimally invasive". \[lines 72, 74 e 75\].

4\. Methods:

\"Patients with other concomitant infections, such as hepatitis B, hepatitis C, dengue, HIV, or bacterial infection, were excluded from this analysis.\" Were they systematically tested? Clarify.

\- At the hospital where the study was conducted all patients undergo careful clinical examination by doctors. Epidemiological, clinical, laboratorial and demographic data of the study patients were obtained from medical records. Any evidence of other chronic infection or comorbidity in the medical records was sufficient not to include the patient in the present analysis.

\- We made changes in this information in the Method section \[lines 112-115, 120-122\].

5\. \"Treatment for all patients was provided in compliance with the recommendations of the Ministry of Health for the treatment of P. vivax infections \[24\].\" Were all blood samples collected before treatment began? Clarify.

\- For all suspected malaria patients seen at the study hospital, the following laboratory tests are performed: thick smear for Plasmodium screening, blood cell count, and basic blood biochemistry. Their results are found in the patient records.

\- We clarified this in the Method section \[lines 112-115, 120-122\].

6\. What is \"microscopy optics\"?

The term \"microscopy optics \" have been replaced in the text to \"microscopic examination of the blood\" \[lines 125-126\].

7\. Discussion:

\"Drug resistance, genomic alterations in the parasite, and changes in the host inflammatory response may have contributed to this clinical phenomenon \[40\].\"

Genomic alterations? Change to parasite genotype selection or similar.

\- We changed the sentence to "parasite genotype selection" as suggested. \[lines 242-243\]

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Reviewer \#2:

Aspartate aminotransferase-to-platelet ratio index (APRI): a potential marker for diagnosis in patients at risk of severe malaria caused by Plasmodium vivax.

Thank you for giving me an opportunity to review this paper. I have read this manuscript with keen interest. The authors have attempted a study with two objectives; i) to describe the clinical and laboratory characteristics of patients with P. vivax infection, and ii) to evaluate the APRI as a method of identifying patients with potentially severe disease.

This is an interesting research area in the light of malaria pre-/elimination context. However, I feel that the manuscript needs substantial improvement on an array of areas.

The followings are not exhaustive, only some examples to improve the quality of presentation.

Abstract

Please, update the abstract based on the comments given below.

Line\# 29...It should be better to describe as 'the objectives', rather than the goal.

\- We changed the sentence to "In the present study, the aspartate aminotransferase-to-platelet ratio index (APRI) was evaluated as a method for identifying patients at risk of severe vivax malaria". \[lines 29-34\].

Line \#32.... I feel, this is a retrospective cohort analysis of the clinical-epidemiological data. The study data were obtained from the medical records.

\- All the studied patients were outpatients and only attended the hospital for the first medical evaluation, not returning for clinical follow-up. No follow-up information on disease progression was obtained in the study. So, only a cross-sectional approach was performed. We added this information in the Methods section. \[lines 116-119\].

\- Therefore, we only had information from the first medical evaluation. By the only cross-sectional approach we were careful not to state that the patients had severe vivax malaria. We just inferred that they were at risk for severe vivax malaria.

Line \# 38.. Please, clarify whether these are 130 patients or 130 patient's records.

\- We changed to "130 patient's records". \[line 40\].

Line \# 40..... It should read as 'severe vivax malaria'.

\- Since the study design did not include patient follow-up to ensure progression to severity, the authors preferred to be careful in interpreting vivax malaria severity in this cross-sectional approach only. Therefore, throughout the manuscript, the inference about severity was parsimonious. We replaced the term \"potentially serious\" to \"at risk of severity\". \[lines 32, 37, 40, 48, 101, 104, 165, 191, 193, 195, 200, 209, 211, 2013, 217, 223, 232, 247, 249, 273-275, 289-290, 302, 304, 306, 331\].

Line \# 44,45,47..... I feel, there is some exaggerations in interpretations.

The ROC value was 0.645 (0.494; 0.795), specificity was 56.0% and accuracy was 65.0%.

\- In fact, the APRI cut-off at 0.74 provided 74% sensitivity to identify patients at risk for severe vivax malaria. We highlighted the high sensitivity and the low specificity in those parts of the Discussion \[line 306\] and Abstract \[lines 49-51\].

\- We highlighted the low APRI specificity in the Discussion section \[lines 240-241, 336\]

\- As showed in lines 309-313, this find was brought to the discussion by the authors: "It is interesting to note that for this study, the greater sensitivity relative to specificity for the APRI does not invalidate its possible clinical application since it is preferable to identify patients with a higher risk of developing severe disease early, even at the risk of erroneous classification due to the high probability of false positives".

Line \# 47.......The authors have concluded that "This simple index can serve as a diagnostic biomarker........."..........The authors need to revise the interpretation and conclusion.

\- We changed the study conclusion to "Our results show that the APRI is elevated in patients with evidence of P. vivax infection. Based on the good APRI sensitivity found in this study, we conclude that this simple index can serve as a diagnostic biomarker to identify patients at risk of severe disease during the acute phase of P. vivax infection." Both in Abstract and Conclusion sections. \[lines 49-51, 347-351\].

TEXT

A substantial improvement in English language/grammar/ punctuation are required throughout the manuscript.

Overall, the current version of manuscript is not well written.

\- The manuscript was translated and edited from Portuguese to English by EDITAGE that states that its translators have English as their native language. We will attach the Certificate of Edition along with our revised manuscript. If the revised manuscript is accepted for publication in PlosOne, we promise to resubmit it to EDITAGE for further English review.

Background

This section is not well written. Also, it is not in sequential order. There is redundant information.

\- A careful review of the text presented in the Introduction (background) section has been made. Several words and phrases have been deleted, changed or inserted to make the text clearer. \[lines 59, 63-64, 72-74, 75, 77-78, 83, 90, 95-97, 102-103, 106-109\]

The study objectives were not well described. I feel, there are two objectives. Please, explicitly describe the objectives.

\- In fact the study has only one objective. We changed the sentence to "The main objective of this study was to evaluate the APRI as a diagnostic tool for identifying patients at risk of P. vivax malaria severity.". \[lines 102-103\].

Methods

Overall, this section is not well presented.

I feel, this is a retrospective cohort analysis of the patient's records. (Please, see my comments to the abstract).

\- All the studied patients were outpatients and only attended the hospital for the first medical evaluation, not returning for clinical follow-up. No follow-up information on disease progression was obtained in the study. So, only a cross-sectional approach was performed. We added this information in the Methods section. \[lines 116-119\].

\- Therefore, we only had information from the first medical evaluation. By the only cross-sectional approach we were careful not to state that the patients had severe vivax malaria. We just inferred that they were at risk for severe vivax malaria.

The authors need to improve this section. It will be better to follow the STROBE checklist.

\- According to reviewer's suggestion we modified the methods section using the STROBE

Checklist. The STROBE checklist of all manuscript will be uploaded as a supplementary file.

Line\# 159.. The authors assessed whether there is normal distribution of the continuous data. This is an appreciable effort.

\- We thank the Reviewer.

Line \# 160-61 The authors stated that they used a non-parametric Mann-Whitney test. In Table 1 (Foot note)....... The results came out from the Fisher's exact test/Chi-squared test for linear trend. Please, clarify.

\- In fact, the information was not complete in the Methods section and in Table 1. The four statistical tests were used: chi-square, chi-square for linear trends in proportions, Fisher's exact test and Man-Whitney test. We changed the text of the statistical analysis in Methods, in order to complete this information. \[lines 170-173, 214-215\]

Results

Overall, this section is not well presented.

Table 1... Title is too long.

The table 1 title was reduced to "Characteristics of the Plasmodium vivax infected patients, according to presence and absence of signs severe vivax malaria." \[line 214\]

Table 1.. Only two parameters (Platelets and APRI ) are significantly different between the two groups.

Severe TCP ( n=1), APRI \> 1,5 (n = 9)

I feel, the authors can provide a correlation between these two parameters.

\- This reviewer\'s comment was not well understood by authors. Since APRI is calculated based on platelet count, it is expected that there is a high correlation between these two parameters. The lower the platelet count the higher the APRI.

\- There is extensive information in the medical literature that platelet counts are not associated with malaria severity. This was highlighted in lines 143-146 and 259-261. Therefore, the weak correlation between AST and platelet count justifies the use of APRI as a combined measure of these two parameters for the assessment of the disease severity.

Line \# 200......... The average APRI value was 1.24. In Table 1, it was 1.2.

Two decimal or 1 decimal?

\- We decided to keep all APRI values to two decimals. \[lines 44, 214-215, 216-218\].

The authors stated, "An APRI cut-off of 0.74 was reasonably sensitive and specific for identification of patients with a higher potential for severe disease".

Please, consider that a chance of getting false positive is considerable (specificity 56%, accuracy 65%).

\- We highlighted this low specificity in the Discussion section \[lines 240-241, 336\]

Line \# 268-269. For this reason, it is hypothesized that the APRI is .....;; by Plasmodium \[23\]. This supporting information is valuable, and it will be much better to describe under "Background".

\- Indeed, the intention of the authors with this sentence is to say that their initial hypothesis was that APRI would be altered in acute vivax malaria based on previous information that the liver is a important target for complications during acute malaria. Therefore, the authors prefer to keep this argument in the Discussion section. We changed the text in order to clarify this. \[line 286\]

Line \# 318. A cut-off point of 0.74 for the APRI value has good sensitivity and specificity to identify ............. I feel, an exaggeration in interpretation as 74% is not representing the specificity. please, rephrase this sentence. \[Also, see my comments to the Abstract\].

\- In fact, the APRI cut-off at 0.74 provided 74% sensitivity to identify patients at risk for severe vivax malaria. We highlighted the high sensitivity and the low specificity in those parts of the Discussion \[line 306\] and Abstract \[lines 49-51\].

\- As showed in lines 309-313, this find was brought to the discussion by the authors: "It is interesting to note that for this study, the greater sensitivity relative to specificity for the APRI does not invalidate its possible clinical application since it is preferable to identify patients with a higher risk of developing severe disease early, even at the risk of erroneous classification due to the high probability of false positives".
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Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Leonardo Jose de Moura Carvalho

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes
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6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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Reviewer \#2: The authors have fully addressed almost all comments.

For a better flow, it still need to polish English language throughout the text.

Thank you
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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